Professor of Medicine University of Washington, Fred Hutchinson Cancer Research Center
Oncology
Dr. Celestia S. Higano, MD
|
|
Give Review
Celestia Higano practices Oncology. She attended University of Massachusetts Medical School. University of Massachusetts Medical School is ranked 49 in research and 12 in primary care medicine She over the years received 2 awards: "America's Top Doctors" and "America's Top Doctors for Cancer". Dr. Celestia S. Higano is a published physician. She published 103 publications, including: 'Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.' She is registered with Medicare.
Publications
- Prostate Cancer: Mapping the course after CHAARTED.
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
- Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate Cancer: results from PREVAIL.
- Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Surviva...
- Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor...
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate Cancer (COU-AA-302): final o...
- Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.
- Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Can...
- Quantitative and stoichiometric Analysis of the microRNA content of exosomes.
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T.
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate Cancer trial.
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
- Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Progno...
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate Cancer treated with sipuleucel-T.
- Pharmacologic Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Can...
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.
- New developments in the treatment of castration-resistant prostate Cancer.
- Intermittent versus continuous androgen deprivation therapy.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate Cancer.
- To Treat or Not to Treat, That Is the Question: The Role of Bone-Targeted Therapy in Metastatic Prostate Cancer.
- Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort.
- Prostate Cancer, version 1.2014.
- Sequencing therapy in advanced prostate Cancer: focus on sipuleucel-T.
- Urological Cancer: α-Emitting radium-223-additional choices, more unknowns.
- A randomized trial of cognitive rehabilitation in Cancer survivors.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate Cancer (SWOG S0421): a randomised phase 3 trial.
- Tumour cell survival mechanisms in lethal metastatic prostate Cancer differ between bone and soft tissue metastases.
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate Cancer: results from an open-label, multicenter phase I/II study.
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer.
- Intermittent versus continuous androgen deprivation in prostate Cancer.
- Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer.
- Characterization of osteoblastic and osteolytic proteins in prostate Cancer bone metastases.
- Abiraterone in metastatic prostate Cancer without previous chemotherapy.
- Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate Cancer.
- Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate Cancer: results from the Univers...
- Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).
- Treatment-induced damage to the tumor microenvironment promotes prostate Cancer therapy resistance through WNT16B.
- Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonm...
- Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer.
- Reply form Authors re: Bertrand Tombal. Continuous Improvement Versus Innovation: The Case for Sipuleucel-T. Eur Urol. In press. DOI:10.1016/j.eururo.2011.11.033.
- New and emerging agents for the treatment of castration-resistant prostate Cancer.
- The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature.
- New treatment options for patients with metastatic castration-resistant prostate Cancer.
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine.
- C11-acetate and F-18 FDG PET for men with prostate Cancer bone metastases: relative findings and response to therapy.
- Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate Cancer treated on a pros...
- Refractory colitis following anti-CTLA4 antibody therapy: Analysis of mucosal FOXP3+ T cells.
- Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate Cancer.
- Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate Cancer.
- CCL2 is induced by chemotherapy and protects prostate Cancer cells from docetaxel-induced cytotoxicity.
- Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate Cancer.
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate Cancer.
- Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate Cancer: data from Southwest Oncology Group Trials 9346 (Intergroup...
- Development of a second-generation antiandrogen for treatment of advanced prostate Cancer.
- Prostate Cancer-associated gene expression alterations determined from needle biopsies.
- Does chemotherapy have a role before hormone-resistant Disease develops?
- Phase II trial of weekly patupilone in patients with castration-resistant prostate Cancer.
- Multimarker circulating DNA assay for assessing blood of prostate Cancer patients.
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate Cancer treated with intermittent androgen ablation.
- Positive surgical margins: the argument for androgen deprivation and chemotherapy.
- COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE Cancer.
- Conventional treatments of localized prostate Cancer.
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate Cancer.
- Histopathological assessment of prostate Cancer bone osteoblastic metastases.
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate Cancer.
- Maintenance of intratumoral androgens in metastatic prostate Cancer: a mechanism for castration-resistant tumor growth.
- Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate Cancer metastatic to bone.
- Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate Cancer: what do we really know?
- Phase II study of KOS-862 in patients with metastatic androgen independent prostate Cancer previously treated with docetaxel.
- Molecular alterations in prostate Carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differ...
- Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate Cancer.
- Annual zoledronic acid: is less more?
- Variation in the definition of biochemical recurrence in patients treated for localized prostate Cancer: the American Urological Association Prostate Guidelines for Lo...
- Estrogenic side effects of androgen deprivation therapy.
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate Cancer.
- Intermittent androgen deprivation: clinical experience and practical applications.
- Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate Cancer.
- The role of bisphosphonates in the treatment of prostate Cancer: recommendations from an expert panel.
- A prospective Analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinica...
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate Cancer.
- Metastases of prostate Cancer express estrogen receptor-beta.
- Understanding treatments for bone loss and bone metastases in patients with prostate Cancer: a practical review and guide for the clinician.
- Osteoporosis in men with prostate Carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
- Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate Cancer.
- Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate Cancer.
- Third international conference on innovations and challenges in prostate Cancer: prevention, detection and treatment.
- Management of bone loss in men with prostate Cancer.
- Bone loss and the evolving role of bisphosphonate therapy in prostate Cancer.
- Phenotypic heterogeneity of end-stage prostate Carcinoma metastatic to bone.
- Expression of the human cachexia-associated protein (HCAP) in prostate Cancer and in a prostate Cancer animal model of cachexia.
- Elevation of cytokine levels in cachectic patients with prostate Carcinoma.
- Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.
- Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate Cancer.
- Prostate Cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
- Chemotherapy-induced monoamine oxidase expression in prostate Carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
- A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate Cancers than in primary prostate ...
- Potential use of custirsen to treat prostate Cancer.
- Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate Cancer.
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
- Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation.
Schools
University of Massachusetts Worcester Campus
Mayo Clinic Rochester
University of Washington
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
University of Massachusetts Medical School
Hospital
-
UW Medicine/Harborview Medical Center -
Seattle Children's Hospital -
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1972689727 | |
| NPPES Provider LastName | HIGANO | |
| NPPES Provider FirstName | CELESTIA | |
| NPPES Provider ZIPCode | 98109 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 52.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972689727 |
| Last Name Of The Provider | HIGANO |
| First Name Of The Provider | CELESTIA |
| View All |
Similar Doctors
|
|
Dr. Vivian G. Oehler, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David G. Maloney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Milder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristine J. Rinn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott S. Tykodi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ajay K. Gopal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Gilbert, MD |
|
|
Dr. Merav Bar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hugh L. Straley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Howard L. West, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larissa A. Korde, MD
This Doctor is OpenDoctor Recommended.
|